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Abstract
Limbal Stem Cell Deficiency (LSCD) encompasses a group of eye disorders 
characterized by abnormal maintenance of the limbal stem cells. This painful 
and potentially blinding condition poses a challenge in transplantation biology; 
whereby whole corneal transplantation would normally fail due to the depletion of 
the recipients’ limbal stem cells. The most preferred technique of management is 
transplantation of ex vivo expanded limbal stem cells to the damaged eyes. This 
article discusses the therapy options for unilateral and bilateral cases of LSCD, 
the clinical outcomes, components of cells and substrates that are currently 
being investigated or have been utilized by this technique, and brings into focus 
the newer therapy of using a scaffold-free cell delivery system to treat LSCD.
Keywords: Limbal stem cells; Limbal stem cell deficiency; Tissue 
engineering; Cell sheet
i.e Steven-Johnson syndrome, ocular cicatricial phemphigoid and 
chronic limbitis. Trauma, surgery and cryotherapy to the limbus, 
radiation and topical instillation or subconjunctival injection of toxic 
drugs are some iatrogenic causes.
In the majority of cases involving corneal blindness, whole corneal 
transplantation is the therapy of choice; but this is not the solution for 
LSCD. Failure of transplantation in this condition lies in the loss of 
host stem cells and thus, inadequate self renewing cells to replenish 
the epithelial surface of the grafts taken from the donor. Due to this, 
the management of LSCD shifts to transplantation of healthy limbal 
tissue to the damaged limbal areas. This follows the rationale that re-
epithelisation will take place when there are residual healthy limbal 
cells in the diseased eye, or a sufficient number of limbal cells are 
replaced by transplanting whole pieces of healthy limbal tissues [13]. 
However, this surgical method will usually involve a large area of graft 
taken from a donor site, thus rendering it susceptible to secondary 
LSCD.
Current Perspective on Tissue Engineering 
for LSC Transplantation
Tissue engineering was first introduced as an interdisciplinary 
approach using cell biology and engineering to restore or enhance 
the biological functions of tissues and organs using substrates 
[14]. A landmark report in 1997 by Pellegrini revealed a successful 
transplantation of ex vivo expanded limbal epithelium grown on a 
fibrin carrier [15]. Another commonly used substrate is the amniotic 
membrane [16]. The outgrowths from the explants originated from 
a contra lateral healthy eye were allowed to proliferate to form a cell 
sheet before transplantation to the damaged eye. The advantage of 
using autologous ex vivo expansion of limbal epithelium is the small 
sized-biopsy taken from the healthy eye which will prevent secondary 
LSCD in the donor eye. The need for a long term immune suppression 
is usually eliminated [17]. These bioengineered tissue constructs 
comprising of a cellular component and a substrate counterpart 
allow the cells to grow and differentiate towards corneal epithelial 
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Introduction
The corneal limbus forms the narrow transition zone between 
the corneal and conjunctival epithelia and is believed to harbour the 
cornea stem cells [1-3]. The limbal stroma is an area rich in blood 
vessels, contains melanocytes, Langerhans cells and abundant with 
nerve supply. Adult stem cells are now believed to reside in most 
tissue populations for regenerative purposes and tissue repair. Stem 
cells are protected from hostile external factors in a specialized 
microenvironment called the “stem cell niche”. It is hypothesized that 
the stem cells for the cornea are deposited deep in the basal layer of 
the limbus [3-7].
More recent advances using the lineage tracing technique in 
K14+ve Confetti mice supported the evidence that mouse limbus 
significantly contributed to self renewal and regeneration of the 
mouse cornea [8,9]. Limbal cells also responded rapidly to major 
wounding compared to the wound healing potential of the long-term 
corneal clones which mainly responded to minor injury [9].
Limbal Stem Cell Deficiency (LSCD)
This is a painful and blinding condition of the eye caused by 
abnormal maintenance of the LSC [10]. It can be broadly categorized 
into unilateral or bilateral involvement, acute or chronic conditions. 
Among the causes are hereditary genetic disorders called aniridia, 
where there is developmental dysgenesis of the anterior chamber 
of the eye due to PAX6 gene mutation [11,12]. Acquired causes of 
LSCD include chemical and thermal injury, inflammatory conditions 
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lineage and proliferate to form an epithelial sheet to be transplanted 
to the ocular surface. The purpose of this is to maintain the corneal 
epithelial barrier function from external insults such as pathogens, 
allergens, desiccation or mechanical injury. 
Clinical Trials for Limbal Stem Cells 
Transplantation 
Translational research involving ex vivo expansion of LSC and 
transplantation to treat LSCD was among the first stem cell tools to 
reach the patients. Using keywords such “limbal stem cell deficiency” 
and “limbal stem cell insufficiency” in a search at the database for 
human clinical trials https://clinicaltrials.gov, we found only 10 
registered clinical trials (one trial on the use of collagenase in a 
tissue culture protocol was disregarded). These clinical trials mainly 
covered the use of established protocols for ex vivo expanded LSC and 
oral mucosa. This implies that the growing numbers of clinical studies 
for the treatment of LSCD remains in the academic institutions 
and laboratories; needing further optimization of protocols before 
materializing into registered clinical trials. Furthermore, the long and 
complex pathways from preclinical trials to regulatory approval and 
consent, Good Manufacturing Practice (GMP)-compliant laboratory 
protocols and industrial partnership for funding of clinical trials 
and production of “accredited tissues” are among the obstacles from 
making these studies nearer to the clinic [18,19]. Till date, Holoclar 
is the only ex-vivo expanded autologous human corneal epithelial 
stem cell product authorized to be used as an advanced therapy 
recommended by The European Medicines Agency (EMA) for the 
treatment of LSCD in the European Union. However, Holoclar still 
awaits comprehensive data report before being adapted for general 
clinical practice. 
The Outcome of Ex Vivo Expanded Limbal 
Epithelial Transplantation
Several investigators have investigated into LSC fate and how 
restoration of the damaged ocular surface takes place after LSC 
transplantation [20]. It is very unlikely that it is due to replacement 
of stem cell numbers alone. It was suggested that LSC transplantation 
has stimulated dormant LSC to renew and proliferate to the site of 
injury. In addition, LSC transplantation was also believed to attract 
circulating corneal progenitors or directly from Bone Marrow (BM) 
to repopulate the site of injured ocular surface by a chemotactic 
stimulus. Studying the LSC fate in different aetiologies of stem cell 
deficiency and the types of tissue transplantation would be a future 
direction to explain the process of cellular restoration. At present, 
there is no consensus on LSC fate in different types of transplantation 
[20-22] such as in penetrating keratoplasty, alone or in combination 
with limbal allograft transplantation, or in the case of ex vivo LSC 
transplantation.
A short term review of 28 clinical studies on cultivated corneal 
epithelial transplantation since 1997 to 2010 shows a success rate of 
67% [23]. This would probably be due to the majority of tissues used 
in these studies being autologous in nature (84%). Another long term 
study on the outcome of cultured limbal epithelial transplantation 
using fibrin as a carrier gave 66% of full success, 19% for partial 
success and 15% of failure rate respectively [24]. In another review 
of clinical outcomes [25], despite the heterogeneity of the type of 
grafts, the biological carrier to transplant LSC, culture methods, and 
the clinical cause of the disease, the overall outcome of 17 studies 
was similar at 67% success rate. In a recent systematic review and 
meta-analysis of LSC transplantation using AM, an almost similar 
outcome was recorded. The success rate and vision improvement 
was at 67% and 62% respectively [26]. Surprisingly, there was no 
significant difference between autografts and allografts. A longer 
post transplantation period of observation is warranted to justify this 
conclusion.
It could not be emphasized enough that long term success of LSC 
transplantation depends on the quality of the grafts or the frequency 
of LSC on the grafts [27]. Rama et al, observed the presence of more 
than 3% of p63+ve stained cells in the holoclones were associated 
with 78% of success rate. The outcome could be improved by a more 
effective identification or isolation of LSC, or the use of stem cell 
enrichment methods such as the side population assay [28,29]. 
Similar to the allogeneic response occurring in solid organ 
transplantations, the issue with allogeneic tissue or cell transplants in 
LSC remains their immunogenicity due to major histocompatibility 
complex mismatch [30]. Major allogeneic responses include the 
“graft-versus-host” immunological reactions which need tolerance-
inducing strategies [31,32].
In the case of total and bilateral LSCD, cultivated oral mucosa 
epithelial transplantation on AM has also been clinically applied 
with promising results [33,34]. This approach when reviewed for 
15 treated eyes showed a success rate of 67% total re-epithelisation, 
without any major complications for a period of at least 34 months. A 
similar method, but in the absence of 3T3 feeders and animal serum 
has also been trialled in two patients with successful regeneration of 
corneal epithelium [35]. However, the phenotypic difference in the 
corneal and oral mucosa epithelia leads to new vascular formation 
and corneal opacity. A secondary penetrating keratoplasty may 
sometimes be performed to achieve a clear central cornea and 
improve visual acuity [36,37]. 
Alternative Sources of Cells 
The lack of donor corneas in sufficient quantity and of sufficient 
quality to generate limbal epithelia for transplantation has motivated 
many clinicians and scientists to search for alternative sources of 
cells for cellular therapy. The option for replacement of adult limbal 
epithelial stem cells sourced from outside the cornea includes human 
Embryonic Stem Cells (ESC) which can be directed to the corneal 
epithelial lineage. Although ESCs have better differentiation and 
expansion potential than adult stem cells their use is hampered by 
ethical issues, regulatory problems and associated funding limitations. 
The use of appropriate ECM cellular matrix i.e. collagen IV, 
laminin or fibronectin in a differential protocol successfully direct 
human ESC into corneal epithelia [38]. In a mouse derived ESC, 
the use of collagen IV as a culture substrate has resulted in corneal 
progenitors which expressed PAX6 and CK12 genes. PAX6 is 
important for ocular development while CK12 has been regarded 
as a specific marker of corneal epithelial differentiation. Indeed, 
transplantation of these corneal progenitors on denuded cornea 
produced epithelial surface re-epithelisation after 24 hours. However, 
restrictions surrounding ESC, namely ethical issues, technique of 
differentiation, accessibility and the costs, have limited the use of 
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ESC for a larger scale translational approach. Presence of human 
leucocyte antigen Class I molecules which are a major immunological 
mediators pose as an immunogeneic challenge which requires tissue 
tolerance mechanisms before ESC transplantation [39,40].
In the meantime, the advent of human induced Pluripotent Stem 
Cells (iPSC) has partly resolved the ethical issues surrounding ESC. 
The use of transcription factors; Oct3/4, Sox2, c-Myc and Klf4 [41], 
on somatic cells can induce pluripotency in these cells, a process 
called “reprogramming”. Hayashi et al. successfully induced cornea 
epithelial cells from human adult dermal fibroblast-derived iPSC and 
human adult corneal limbal-derived iPSC [42] by using the stromal 
cell-derived inducing activity method. In an animal model, mouse 
iPSC had been demonstrated to differentiate into corneal epithelial-
like cells when co-cultured with corneal stromal cells in the presence 
of additional factors such as β-Fetal growth factor, Epidermal 
Growth Factor (EGF) and nerve growth factor [43]. Transcriptionally 
induced pluripotent cells could be a source of tumour formation 
[44,45] due to lentiviral integration at the site of gene promoters, 
and poses the problem of a reliable cellular differentiation. There is 
also a concern about immunogenicity when used in transplantation 
[46]. The latter is reported to be related to aberrant methylation and 
epigenetic memory to their tissue of origin and dependent on the 
reprogramming methods. 
MSCs have tri-lineage potential into adaptogenic, chondrogenic 
and osteogenic differentiation, have paracrine secretions of 
immunomodulatory molecules and immune-suppressive properties; 
ideal for cell-based therapeutic potentials. MSCs were originally 
isolated from BM, are conveniently isolated from other non-marrow 
tissue sources such as from the musculoskeletal system [47], adipose 
tissue [48], oral tissues [49] and umbilical cord blood [50]. Most 
studies utilizing MSC for LSCD were conducted in animals [51-
53]. Almaliotis et al. recently used injectable MSC into the corneal 
stroma and conjunctiva of alkaline-induced injury in rabbits with a 
remarkable outcome [54]. Comparative studies between BM-derived 
and LSC showed comparable results for ocular surface regeneration in 
a rabbit model [48]. Although MSC-based therapies for the treatment 
of LSCD are rapidly evolving, the field is in need of further knowledge 
on the mechanism of action, standardized culture protocols and 
human clinical trials. 
Substrates for Cell-Based Therapy
The second major component in tissue engineering is the 
biomaterials used as the substrate or scaffolds for cell delivery. The 
initial focus was to replicate the physical and mechanical properties 
of the target tissues. Prospectively, more emphasis is being given to 
develop “biomimetic” substrates which integrate the substrates with 
the biological environment resembling closely the natural topography 
of the limbal epithelial crypts as the supportive Extra Cellular Matrix 
(ECM) [55]. An ideal carrier substrate has often been described to 
have not only optical clarity, but also able to withstand the culture 
conditions, flexible to the shape of the cornea and quite tough for 
surgical manipulation including the suturing.
Biological Substrates
Fibrin sheet
Historically, the use of biological substrates has been the strategy 
for LSC transplantation when fibrin sheet was first utilized for this 
indication [15]. A mixture of fibrinogen and thrombin was placed 
on a plastic ring to allow a coagulation cascade. Primary limbal 
keratinocytes were grown on feeder layers on this fibrin sheet and 
the cell to matrix construct were then transplanted to patients’ eyes 
[56]. A clinical trial involving larger number of patients showed a 
success rate of 76.6% up to 10 years [27]. Fibrin gels are transparent, 
absorbable and easier to manipulate however, they present a risk of 
contamination [57] and cause LSC differentiation [58].
Human amniotic membrane
AM as part of the carrier system to transfer limbal epithelial sheets 
has been the substrate of choice to restore ocular surface disorders 
[59]. AM facilitates re-epithelisation and has been shown to have 
anti-inflammatory [60], anti-angiogenic [61,62], and anti-scarring 
properties [63]. To date, AM has been the most widely used substrate 
to deliver LSC to the ocular surface. Several modifications have been 
tried to provide different forms of AM to improve its quality as a 
carrier, including the use of denuded AM over an intact membrane 
[33]. 
The drawbacks of AM are the difficulty to sustain the donor supply 
and clinical variations in the tissues which might affect the growth 
conditions. The screening of AM for transmission of diseases is costly 
and ineffective because it does not totally rule out viral transmission. 
Additionally, the use of scaffolds or substrates as implants is associated 
with risk of surgical infections [64]. Hence, researchers have explored 
the potentials of other materials and used new strategies to develop 
synthetic tissue-engineered constructs to improve the outcome of 
LSC transplantation for ocular surface regeneration. 
Contact Lens (CL)
Di Girolamo group introduced CL populated by cellular 
expansion of limbal/conjunctival explants using a xeno-free culture 
system for autologous transplantation in partial and total LSCD 
[65]. Sixteen eyes of patients with multiple aetiologies showed an 
impressive restoration of epithelium in 63% of cases at 2.5 years of 
follow up. This delivery method of cell-based therapy is attractive 
in many ways; it uses a regular CL which makes the cost relatively 
affordable, surgically it is easier to manipulate, and transparency is 
not a problem. However, the explants method is preferable to the cell 
suspension method where multiple limbal/conjunctival biopsies from 
different sites need to be harvested to obtain an adequate size of cell 
sheet due to poor proliferation of cells from the explants on CL. 
Collagen
Collagen forms a major component of the cornea stroma and 
naturally remodelled by the host cells. Hydrated collagens (hydrogels) 
are biocompatible, inert, biodegradable and attractive to replace or to 
complement AM. Hydrogels are more structurally uniformed and the 
physical and mechanical properties can be modified to suit cellular 
proliferation [66]. Hydrogels are made up of a 3D network of polymers 
and water, comprised of macro-molecules connected by electrostatic 
forces, hydrogen bond, or covalent links. As a scaffold, hydrogels 
can encapsulate cells and biomolecules as a cellular niche. However, 
the large composition of water weakens the scaffolds. Cross-linking 
of collagen with other substances improve the mechanical property 
of a scaffold [67] however this might alter cellular remodelling and 
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impairs the biomimetic property of the substrate [68]. Fibrin, collagen, 
plastically compressed and alginate hydrogels [69-71] are some of 
the examples used in clinical studies for LSCD treatment. The use of 
hydrogels for cellular-based therapies needs a continuous search for 
the ideal and optimum balance of the composition of the polymer 
materials i.e. water, ionic cross-linking, pores and permeation. These 
properties will determine cellular adhesion and the biocompatibility 
of the materials for tissue engraftment [72].
Plastic compressed collagen
Plastic compression is a technique used to extract water from a 
collagen hydrogel by downward absorption onto a filter paper [73]. 
This is performed to increase the mechanical strength of the hydogels. 
Levis et al demonstrated scaffolds made of compressed collagen gel 
when compared to denuded AM to be a better biomimetic substrate 
for the growth of Limbal Epithelial Cells (LEC) [74]. This proved to 
be mechanically strong, thin and transparent. Additionally, these 
collagen can be further molded into 3D niche structure mimicking 
the limbal crypts to allow for better LSC growth [55]. However further 
standardization of the methods and clinical data is necessary before 
taking it further as a cell-based therapy for LSCD [75].
Nanofibers
Fabricated nanofibers can be produced by electro spinning 
methods where biocompatible substrates and polymers are 
interwoven together [76]. This three-dimensional structure allows a 
large surface area and a suitable environment for stem cells growth 
and transfer. In a recent study, fibrous nanoscaffolds from poly-ε-
caprolactone demonstrated numerous advantageous properties of 
controlled shape and porosity, and have a high surface: volume ratio. 
As a 3D biocompatible structure, this can mimic the physiological 
ECM cellular matrix, used for synthetic ocular surface regeneration. 
This scaffold system was shown to be biocompatible with LEC and 
use of these with cells resulted in good cellular adhesion and cell 
proliferation [77]. A recent clinical study using MSCs seeded on 
nanofibers showed significant wound healing from alkaline injury 
with suppression of inflammation in a rabbit model [78].
Silk fibroin
A biodegradable material has the advantage of variable 
degradation rate for the viable cells to be released at the site of injury. 
Silk fibroin which is synthesized from the cocoon of silkworm has 
been found to be a useful substrate for LEC; it was able to support 
corneal epithelial proliferation, differentiation and stratification 
[79,80], although induction of an inflammatory response in the host 
is a primary concern. The cost of production of a natural silk material 
for bioengineering is an area of concern. A combination of silk with 
synthetic materials such as polymers and ceramic for the purpose 
of cell-based therapy in the cornea is an interesting area for further 
investigations.
Keratin films
Keratins are a group of structural proteins present on the epithelia 
of hard or filamentous structures such as the hair, nails, feathers 
and hoofs of higher vertebrates. Keratin makes these structures to 
be water insoluble, however its mechanical strength and capability 
for cells to grow and proliferate on modified keratin-coated culture 
surfaces have garnered a lot of interest in tissue engineering. Reichl 
et al. demonstrated in vitro human corneal epithelial growth on 
modified keratin films that was comparable to AM [81]. By mixing 
two types of keratin dialysate and subjected it to multiple steps in 
processing, the keratin films that were produced were mechanically 
strong for surgical handling but encountered difficulty such as suture 
loosening; which needs further modification to the keratin structures. 
There is an increasing need to develop a synthetic, biocompatible 
and slowly biodegradable material which could be used as substitute 
for the AM. The use of a synthetic material would lessen the risk of 
infection. A substrate which is resilient, biocompatible, and able to 
adapt to the surface of the eye is an ideal carrier system for delivering 
of cultured corneal epithelium and a viable option for cellular-based 
therapy. A summary of tissue-engineered substrates is provided in 
Table 1.
Emerging Techniques and Future Directions
Decellularised tissues
Strategies involving decellularisation of tissues and organs have 
been of interest to LSC biologists in the past decade. This technique 
involves complete removal of cellular components, cellular materials 
and antigens from tissues to reduce its immunogenicity [82]. This 
is done while maintaining the corneal structure and the ECM. 
Decellularisation can be achieved by using chemical and enzymatic 
Materials Advantages Disadvantages
Human Amniotic 
membrane
Stimulates re-epithelisation, have anti-inflammatory, anti-angiogenic 
and anti-scarring properties
Semi-transparent, donor to donor variability in the quality of tissues, 
risk of disease transmission and limited strength
Fibrin sheet Transparent, absorbable, elastic and easier to manipulate Risk of contamination and cause early LSC differentiation
Collagen Biocompatible, relatively cheap, less immunogenic Collagen hydrogels are mechanically weak, early contraction and 
easily degraded
Plastically 
compressed collagen
Transparent, mechanically strong and shaped to the ocular surface. 
Biocompatible for epithelial growth and stratification
Standardization of methods to achieve desired collagen 
concentration and density/stiffness to cater to collagen biomimetic 
properties.
Silk fibroin Biodegradable, and compatible with cellular growth and proliferation.
Cost of production of natural silk and potential triggering of 
inflammatory response.
Contact Lens (CL)
Mechanically strong, transparent and easy to handle. Multiple 
biopsies harvested and grow in cultures is advantageous for repeat 
procedures.
Synthetic CL may not be an effective biological substrate for cell-
based expansion of limbal/conjunctival explants resulting in poor 
proliferation of cells and loss of SC.
Nanofibers
Three-dimensional structure of nanoscaffolds allows a large surface 
area and a conducive environment for cellular growth along the fibers.
Elecrospinning fibers consisting of polymers and solvents could be 
toxic to the cells.
Keratin films
Modification to the structures can produce keratin films which are 
transparent, absorbable and easy for surgical handling. Cellular 
growth and proliferation are comparable to AM
Optimisation of the structures of keratin films imperative to achieve 
a biocompatible construct, better for suturing, non-toxic and non-
immunogenic.
Table 1: Biomaterials used in corneal epithelial tissue engineering in the clinical studies for LSCD.
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methods, followed by re-seeding with new cells, a process called 
“scaffold recellularisation” [83,84]. The challenge is to find the 
right seeding density and the choice of repopulating the surface 
or via injecting into the scaffold. Maintaining a close balance of 
preserving structural, mechanical and physiological properties of 
the decellularised cornea and reducing cellular immunogenicity are 
among the challenges in this area.
Cell sheet tissue-engineered system
A technique developed to escape from any use of carrier 
system is a new temperature-responsive polymer e.g. Poly 
N-isopropylacrylamide (PIPAAm) as a cell sheet engineering 
system introduced by Okano group and first used in the cornea by 
Nishida in 2004 [85]. This method allows transfer of cells and the 
ECM to the ocular surface at different temperature conditions in the 
absence of a scaffold. PIPAAm polymer and its co-polymer show a 
hydrophobic state at 37oC and at this temperature cells would adhere 
and proliferate. At 32oC and below, the cells are detached because of 
polymer hydration, which allows harvesting of the cells in a mono 
layer cell sheet while maintaining cell-to-cell and cell-to-ECM 
contact. Cell sheet fabricated hepatocytes and β-islet cells have been 
engineered for clinical treatment of liver failure and type I diabetes 
mellitus [86,87]. As for the treatment of cardiac diseases, a plethora 
of options are available from cardiomyocytes cell sheets, myoblast 
sheets, MSC sheets and cardiac progenitor cell sheets for cardiac 
regeneration [88]. 
Tissue-engineering in the cornea has often maintained the use 
of a carrier system for delivery of the cells. A carrier system has 
the disadvantages of an exposure to infections and transmission 
of pathogens, especially in the case of biological scaffolds. Both of 
these factors can hinder tissue integration and affect the survival of 
tissue transplantation. Suture less techniques as advocated in the 
transplantation of cell sheets also have the advantages of reducing 
inflammation post-operatively [85].
The cell sheet engineering system has expanded to include 
autologous oral mucosa cell sheet fabrication for the treatment of 
bilateral cases of LSCD; a potential alternative carrier to AM [89,90]. 
In a study of 26 eyes with bilateral LSCD, transplanted oral mucosa 
cell sheets supported successful regeneration of the ocular surface 
with 64% success rate, reduced vascularization and demonstrated a 
safe and well-tolerated product [90]. This suggests the therapy would 
also be beneficial for LSCD caused by ocular infection, aggressive 
surgery at the limbus, contact lens wear and chemical injuries that 
can contribute to corneal damage. Soon the advances of this system 
will also breach the barriers surrounding corneal endothelial [91] and 
retinal pigment epithelial transplantation [92]. 
Scaffold-free tissue engineered cellular tools have advantages 
over many scaffolds currently available due to their high cellular 
availability and long term engraftment. This might be due to the non-
invasive thermo-responsive cellular detachment method allowing 
cells to maintain its ECM, surface proteins, growth factors receptors, 
ion channel and junctional proteins, which are vital for cellular 
differentiation [93,94]. However, the disadvantages of cellular sheet 
approach are possibly the premature detachment of cells or insufficient 
contact of transplanted cells on the corneal surface. In addition, the 
costs of the system and the time involved in the manufacturing of 
autologous cell sheets are part of the disadvantages. These methods 
need to be further refined to include protocols to assess tissue viability, 
the quality of tissue constructs and safety assessment. The quality of 
cells in the tissue construct is vital to ensure permanent tissue repair 
and successful engraftment.
Conclusion
There have been significant developments in tissue engineering-
based therapeutic tools for the treatment of LSCD. Ex vivo expanded 
LSC transplantation has been proven to be able to reconstruct the 
ocular surface in LSCD eyes using a biological scaffold system which 
provides transfer of proliferative cells to the target site. The search 
for the ultimate construct has posed the clinicians, scientists and 
the industry with many challenges before it can be realized into 
human clinical trials and clinical practice. Future directions in this 
field should focus on the development of a high speed, consistent in 
quality, affordable cell propagation system, accredited by regulatory 
bodies, and accessible to many users.
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